Drug Trial Radar · NCT07371468
A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)
Last checked: Nov 20, 2026Latest source record: Jun 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
44
Planned (sponsor's estimate)
Start
Feb 10, 2026
Primary completion
Mar 15, 2028
Study completion Mar 15, 2028
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jan 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2-part study of GSK5926371 in participants with autoimmune rheumatic diseases (ARD). In part 1, participants will receive different doses of GSK5926371 to find a suitable priming dose. In part 2, participants will receive GSK5926371 at doses based on data from part 1. The study is aimed at testing if GSK5926371 is safe, well-tolerated, how the body processes the study drug, how it works in the body, and whether it triggers any immune responses.
Conditions
- Systemic Lupus Erythematosus
Interventions
GSK5926371Biological
GSK5926371 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1 and Part 2: Number of Participants with Adverse Events (AEs) and Serious AEs (SAEs)Time frame: Up to 196 days
Locations
19 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
San Miguel de Tucumán, Argentina · Recruiting
GSK Investigational Site
Campinas, São Paulo, Brazil · Recruiting
GSK Investigational Site
São Paulo, São Paulo, Brazil · Recruiting
GSK Investigational Site
Bordeaux, France · Recruiting
GSK Investigational Site
Toulouse, France · Recruiting
GSK Investigational Site
Cona, Ferrara, Italy · Recruiting
GSK Investigational Site
Fukuoka, Japan · Recruiting
GSK Investigational Site
Hiroshima, Japan · Recruiting
GSK Investigational Site
Hokkaido, Japan · Recruiting
GSK Investigational Site
Panama City, Panama · Recruiting
GSK Investigational Site
Panama City, Panama · Recruiting
GSK Investigational Site
Panama City, Panama · Recruiting
GSK Investigational Site
Poznan, Poland · Recruiting
GSK Investigational Site
Warsaw, Poland · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Taipei, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.